Changes to the varicella and pertussis immunisation schedule in Germany 2009: Background, rationale and implementation

Eurosurveillance

Volumn 15, Issue 16, 2010, Pages 16-20

  Wiese Posselt, M ^a   Hellenbrand, W ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; MEASLES MUMPS RUBELLA VACCINE; PERTUSSIS VACCINE;

ARTICLE; CHICKENPOX; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; GERMANY; HEALTH CARE PERSONNEL; HUMAN; IMMUNIZATION; IMMUNOGENICITY; PERTUSSIS; VACCINATION;

EID: 77951961732     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Robert Koch-Institut. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut. [Recommendation of the Standing Vaccination Commission (STIKO) at the Robert Koch-Institute]. Epid Bull 2009;30. [German]. Available from: http://www.rki.de/cln_160/nn_195850/DE/Content/Infekt/Impfen/Impfempfehlungen/Impfempfehlungen__node.html?__nnn=true
2. Siedler A, Arndt U. Impact of the routine varicella vaccination programme on varicella epidemiology in Germany. Euro Surveill. 2010;15(13). pii=19530. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19530
3. Robert Koch-Institut. Empfehlungen der Ständigen Impfkommission am Robert Koch-Institut. [Recommendation of the Standing Vaccination Commission (STIKO) at the Robert Koch-Institute]. Epid Bull 2004;30:235-50. [German].
4. Glaxo Smith Kline: Product information of Priorix-Tetra®. October 2007.
5. Sanofi Pasteur MSD: Product information of Varivax®. August 2008.
6. Glaxo Smith Kline: Product information of Varilrix®. August 2008.
7. Robert Koch-Institut. Zur Sentinel-Surveillance der Varizellen in Deutschland. [Regarding the sentinal surveillance of varicella in Germany]. Epid Bull. 2008;8;61-4. Available from: http://www.rki.de/cln_160/nn_969736/DE/Content/Infekt/EpidBull/Archiv/2008/08/Tabelle.html?__nnn=true [German]
8. Robert Koch-Institut. [Gemeinsamer Varizellen-Workshop von AGMV und BaVariPro]. Epid Bull. 2010;8:69-75. [German]
9. Spackova M, Wiese-Posselt M, Dehnert M, Matysiak-Klose D, Heininger U, Siedler A. Comparative varicella vaccine effectiveness during outbreaks in day-care centres. Vaccine. 2010;28(3):686-91.
10. Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1996;45(RR-11). Available from: www.cdc.gov/mmwr/preview/mmwrhtml/00042990.htm
11. Guris D, Jumaan AO, Mascola L, Watson BM, Zhang JX, Chaves SS, et al. Changing varicella epidemiology in active surveillance sites -- United States, 1995-2005. J Infect Dis. 2008;197(Suppl 2):S71-5.
12. Centers for Disease Control: Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR04);1-40.
13. Seward JF, Marin M, Vázquez M: Varicella vaccine effectiveness in the US vaccination program: a review. J Infect Dis. 2008;197(Suppl 2):S82-9.
14. Miron D, Lavi I, Kitov R, Hendler A. Vaccine effectiveness and severity of varicella among previously vaccinated children during outbreaks in day-care centers with low vaccination coverage. Pediatr Infect Dis J. 2005;24(3):233-6.
15. Sheffer R, Segal D, Rahamani S, Dalal I, Linhart Y, Stein M, et al. Effectiveness of the Oka/GSK attenuated varicella vaccine for the prevention of chickenpox in clinical practice in Israel. Pediatr Infect Dis J. 2005;24(5):434-7.
16. Passwell JH, Hemo B, Levi Y, Ramon R, Friedman N, Lerner-Geva L. Use of a computerized database to study the effectiveness of an attenuated varicella vaccine. Pediatr Infect Dis J. 2004;23(3):221-6.
17. Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, et al. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Pediatr Infect Dis J. 2008;27(8):724-30.
18. Vesikari T, Baer M, Willems P. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Pediatr Infect Dis J. 2007;26(2):153-8.
19. Kuter B, Matthews H, Shinfield H, Black S, Dennehy P, Watson B, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J. 2004;23:132-7.
20. Centers for Disease Control and Prevention: Advisory Committee on Immunization Practices (ACIP): ACIP Presentation Slides: October 2008 Meeting: MMRV vaccine safety.
21. Wendelboe AM, Njamkepo E, Bourillon A, Floret DD, Gaudelus J, Gerber M et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J. 2007;26(4):293-9.
22. Ständige Impfkommission am Robert Koch-Institut. Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Zusätzliche Pertussis-Impfung im Erwachsenenalter als Tdap-Kombinationsimpfung bei der nächsten fälligen Td-Impfung - Empfehlung und Begründung. [Communication from the Standing Vaccination Commission (STIKO) at the Robert Koch-Institute]. Epid Bull 2009;31:299-311. [German].
23. W, Beier D, Jensen E, Littmann M, Meyer C, Oppermann H et al. The epidemiology of pertussis in Germany: past and present. BMC Infect Dis. 2009;9(22). Available from: http://www.biomedcentral.com/1471-2334/9/22.
24. Riffelmann M, Littmann M, Hülße C, O'Brien J, Wirsing von Konig CH, KRESH-Studienärzte. Pertussis bei Erwachsenen: Häufigkeit, Symptome und Kosten. [Pertussis: incidence, symptoms and costs]. Dtsch Med Wochenschr. 2006;131:2829-34. [German].
25. De Serres G, Shadmani R, Duval B, Boulianne N, Déry P, Douville Fradet M et al. Morbidity of pertussis in adolescents and adults. J Infect Dis. 2000;182(1):174-9.
26. Ständige Impfkommission am Bundesgesundheitsamt. Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Erweiterung der beruflichen Indikationen für eine Pertussis-Impfung. [Communication from the Standing Vaccination Commission (STIKO) at the Robert Koch-Institute]. Epid Bull 2009;31:311-3. [German].
27. Müller-Pebody B, Crowcroft NS, Zambon MC, Edmunds WJ. Modelling hospital admissions for lower respiratory tract infections in the elderly in England. Epidmiol Infect. 2006;134(6):1150-7.
28. Lee G, Lett S, Schauer S, LeBaron C, Murphy T, Rusinak D et al. Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis 2004;39(11):1572-80.
29. Postels-Multani S, Wirsing von Koenig CH, Schmitt HJ, Bock HL, Bogaerts H. Symptoms and complications of pertussis in adults. Infection. 1995;23(3):139-42.
30. Kretsinger K, Broder K, Cortese MM, Joyce PM, Ortega-Sanchez IR, Lee GM et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep. 2006;55(RR-17):1-37.
31. Trollfors B, Rabo E. Whooping cough in adults. Br Med J. 1981;283:696-7.
32. Ständige Impfkommission am Robert Koch-Institut. Appendix to: Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Zusätzliche Pertussis-Impfung im Erwachsenenalter als Tdap-Kombinationsimpfung bei der nächsten fälligen Td-Impfung - Empfehlung und Begründung. [Standing Vaccination Commission (STIKO) at the Robert Koch-Institute]. Epid Bull 2009;31:299-311. [German].
33. Lee GM, Riffelmann M, Wirsing von Konig CH. Cost-effectiveness of adult pertussis vaccination in Germany. Vaccine. 2008;26(29-30):3673-9.
34. Lee GM, Murphy TV, Lett S, Cortese MM, Kretsinger K, Schauer S et al. Cost effectiveness of pertussis vaccination in adults. Am J Prev Med. 2007;32(3):186-93.
35. Purdy KW, Hay JW, Botteman MF, Ward JI. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis 2004;39:20-8.
36. Poethko-Müller C, Kuhnert R, Schlaud M. Vaccination coverage and predictors for vaccination level. Results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007;50(5-6):851-62.
37. Rohani P, Earn DJ, Grenfell BT. Impact of immunisation on pertussis transmission in England and Wales. Lancet 2000;355(9200):285-6.
38. Taranger J, Trollfors B, Bergfors E, Knutsson N, Sundh V, Lagergard T et al. Mass vaccination of children with pertussis toxoid -- decreased incidence in both vaccinated and nonvaccinated persons. Clin Infect Dis 2001;33(7):1004-10.
39. Wendelboe A, Hudgens M, Poole C, Van Rie A. Estimating the role of casual contact from the community in transmission of Bordetella pertussis to young infants. Emerg Themes Epidemiol. 2007;4(1):15.
40. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005;24(5 Suppl):S58-61.
41. Aguas R, Goncalves G, Gomes MG. Pertussis: increasing disease as a consequence of reducing transmission. Lancet Infect Dis. 2006;6(2):112-7.